{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:14:22Z","timestamp":1794878062510,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Rennes"},{"DOI":"10.13039\/501100001677","name":"Inserm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007543","name":"ANSM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolism is involved in both pharmacology and toxicology of most xenobiotics including drugs. Yet, visualization tools facilitating metabolism exploration are still underused, despite the availibility of pertinent bioinformatics solutions. Since molecular networking appears as a suitable tool to explore structurally related molecules, we aimed to investigate its interest in in vitro metabolism exploration. Quetiapine, a widely prescribed antipsychotic drug, undergoes well-described extensive metabolism, and is therefore an ideal candidate for such a proof of concept. Quetiapine was incubated in metabolically competent human liver cell models (HepaRG) for different times (0\u00a0h, 3\u00a0h, 8\u00a0h, 24\u00a0h) with or without cytochrom P450 (CYP) inhibitor (ketoconazole as CYP3A4\/5 inhibitor and quinidine as CYP2D6 inhibitor), in order to study its metabolism kinetic and pathways. HepaRG culture supernatants were analyzed on an ultra-high performance liquid chromatography coupled with tandem mass spectrometry (LC-HRMS\/MS). Molecular networking approach on LC-HRMS\/MS data allowed to quickly visualize the quetiapine metabolism kinetics and determine the major metabolic pathways (CYP3A4\/5 and\/or CYP2D6) involved in metabolite formation. In addition, two unknown putative metabolites have been detected. In vitro metabolite findings were confirmed in blood sample from a patient treated with quetiapine. This is the first report using LC-HRMS\/MS untargeted screening and molecular networking to explore in vitro drug metabolism. Our data provide new evidences of the interest of molecular networking in drug metabolism exploration and allow our in vitro model consistency assessment.<\/jats:p>","DOI":"10.1038\/s41598-020-77106-x","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T11:04:49Z","timestamp":1605524689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["New insights into quetiapine metabolism using molecular networking"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5907-2450","authenticated-orcid":false,"given":"Brendan","family":"Le Dar\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gicquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"77106_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bph.13346","volume":"173","author":"AJ Cross","year":"2016","unstructured":"Cross, A. J. et al. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models: translational pharmacology of quetiapine. Br. J. Pharmacol. 173, 155\u2013166 (2016).","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl 13","key":"77106_CR2","first-page":"5","volume":"63","author":"CB Nemeroff","year":"2002","unstructured":"Nemeroff, C. B., Kinkead, B. & Goldstein, J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J. Clin. Psychiatry 63(Suppl 13), 5\u201311 (2002).","journal-title":"J. Clin. Psychiatry"},{"key":"77106_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1124\/dmd.112.045237","volume":"40","author":"GV Bakken","year":"2012","unstructured":"Bakken, G. V., Molden, E., Knutsen, K., Lunder, N. & Hermann, M. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab. Dispos. 40, 1778\u20131784 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"77106_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/molecules24020310","volume":"24","author":"L Beloti","year":"2019","unstructured":"Beloti, L., Miranda, L. & Queiroz, M. Butyl methacrylate-co-ethylene glycol dimethacrylate monolith for online in-tube SPME-UHPLC-MS\/MS to determine chlopromazine, clozapine, quetiapine, olanzapine, and their metabolites in plasma samples. Molecules 24, 310 (2019).","journal-title":"Molecules"},{"key":"77106_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane, C. L. & Nemeroff, C. B. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin. Pharmacokinet. 40, 509\u2013522 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"77106_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/bmc.2672","volume":"26","author":"DS Fisher","year":"2012","unstructured":"Fisher, D. S., Handley, S. A., Taylor, D. & Flanagan, R. J. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS\/MS: Measurement of quetiapine and four metabolites by LC-MS\/MS. Biomed. Chromatogr. 26, 1125\u20131132 (2012).","journal-title":"Biomed. Chromatogr."},{"key":"77106_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182603f62","author":"DS Fisher","year":"2012","unstructured":"Fisher, D. S., Handley, S. A., Flanagan, R. J. & Taylor, D. M. Plasma concentrations of quetiapine, N-desalkylquetiapine, O-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors. Ther. Drug Monit. https:\/\/doi.org\/10.1097\/FTD.0b013e3182603f62 (2012).","journal-title":"Ther. Drug Monit."},{"key":"77106_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nbt.3597","volume":"34","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. Sharing and community curation of mass spectrometry data with global natural products social molecular networking. Nat. Biotechnol. 34, 828\u2013837 (2016).","journal-title":"Nat. Biotechnol."},{"key":"77106_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2550","author":"S Allard","year":"2018","unstructured":"Allard, S., Allard, P.-M., Morel, I. & Gicquel, T. Application of a molecular networking approach for clinical and forensic toxicology exemplified in three cases involving 3-MeO-PCP, doxylamine, and chlormequat. Drug Test. Anal. https:\/\/doi.org\/10.1002\/dta.2550 (2018).","journal-title":"Drug Test. Anal."},{"key":"77106_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11306-019-1565-7","volume":"15","author":"S Zhou","year":"2019","unstructured":"Zhou, S. et al. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine. Metabolomics 15, 104 (2019).","journal-title":"Metabolomics"},{"key":"77106_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cbpa.2016.12.022","volume":"36","author":"P-M Allard","year":"2017","unstructured":"Allard, P.-M., Genta-Jouve, G. & Wolfender, J.-L. Deep metabolome annotation in natural products research: towards a virtuous cycle in metabolite identification. Curr. Opin. Chem. Biol. 36, 40\u201349 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"77106_CR12","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1021\/acs.analchem.5b04804","volume":"88","author":"P-M Allard","year":"2016","unstructured":"Allard, P.-M. et al. Integration of molecular networking and in-silico MS\/MS fragmentation for natural products dereplication. Anal. Chem. 88, 3317\u20133323 (2016).","journal-title":"Anal. Chem."},{"key":"77106_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-019-02062-9","author":"B Le Dar\u00e9","year":"2019","unstructured":"Le Dar\u00e9, B. et al. A case of fatal acebutolol poisoning: an illustration of the potential of molecular networking. Int. J. Legal Med. https:\/\/doi.org\/10.1007\/s00414-019-02062-9 (2019).","journal-title":"Int. J. Legal Med."},{"key":"77106_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-020-00531-0","author":"S Allard","year":"2020","unstructured":"Allard, S., Le Dar\u00e9, B., Allard, P.-M., Morel, I. & Gicquel, T. Comparative molecular networking analysis of a Rauwolfia plant powder and biological matrices in a fatal ingestion case. Forensic Toxicol. https:\/\/doi.org\/10.1007\/s11419-020-00531-0 (2020).","journal-title":"Forensic Toxicol."},{"key":"77106_CR15","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.035873","author":"L Guo","year":"2010","unstructured":"Guo, L. et al. Similarities and differences in the expression of drug metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab. Dispos. https:\/\/doi.org\/10.1124\/dmd.110.035873 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"77106_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1517\/17425255.2012.685159","volume":"8","author":"TB Andersson","year":"2012","unstructured":"Andersson, T. B., Kanebratt, K. P. & Kenna, J. G. The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin. Drug Metab. Toxicol. 8, 909\u2013920 (2012).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"77106_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/hep.21536","volume":"45","author":"V Cerec","year":"2007","unstructured":"Cerec, V. et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45, 957\u2013967 (2007).","journal-title":"Hepatology"},{"key":"77106_CR18","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1124\/dmd.109.031831","volume":"38","author":"SN Hart","year":"2010","unstructured":"Hart, S. N. et al. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab. Dispos. 38, 988\u2013994 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"77106_CR19","doi-asserted-by":"publisher","first-page":"104842","DOI":"10.1016\/j.tiv.2020.104842","volume":"66","author":"C Hugbart","year":"2020","unstructured":"Hugbart, C. et al. Non-oxidative ethanol metabolism in human hepatic cells in vitro: Involvement of uridine diphospho-glucuronosyltransferase 1A9 in ethylglucuronide production. Toxicol. in Vitro 66, 104842 (2020).","journal-title":"Toxicol. in Vitro"},{"key":"77106_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1124\/dmd.105.006759","volume":"34","author":"C Aninat","year":"2006","unstructured":"Aninat, C. et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. Biol. Fate Chem. 34, 75\u201383 (2006).","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"77106_CR21","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s00204-018-2300-2","volume":"92","author":"N Quesnot","year":"2018","unstructured":"Quesnot, N. et al. Production of chlorzoxazone glucuronides via cytochrome P4502E1 dependent and independent pathways in human hepatocytes. Arch. Toxicol. 92, 3077\u20133091 (2018).","journal-title":"Arch. Toxicol."},{"key":"77106_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02742-1","author":"SK Manier","year":"2020","unstructured":"Manier, S. K., Wagmann, L., Flockerzi, V. & Meyer, M. R. Toxicometabolomics of the new psychoactive substances \u03b1-PBP and \u03b1-PEP studied in HepaRG cell incubates by means of untargeted metabolomics revealed unexpected amino acid adducts. Arch. Toxicol. https:\/\/doi.org\/10.1007\/s00204-020-02742-1 (2020).","journal-title":"Arch. Toxicol."},{"key":"77106_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1389201018666171122124401","volume":"18","author":"C Richeval","year":"2018","unstructured":"Richeval, C. et al. In vitro characterization of nps metabolites produced by human liver microsomes and the HepaRG cell line using liquid chromatographyhigh resolution mass spectrometry (LC-HRMS) analysis: application to furanyl fentanyl. Curr. Pharm. Biotechnol. 18, 806\u2013814 (2018).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"77106_CR24","doi-asserted-by":"publisher","first-page":"e1006089","DOI":"10.1371\/journal.pcbi.1006089","volume":"14","author":"RR Da Silva","year":"2018","unstructured":"Da Silva, R. R. et al. Propagating annotations of molecular networks using in silico fragmentation. PLoS Comput. Biol. 14, e1006089 (2018).","journal-title":"PLoS Comput. Biol."},{"key":"77106_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41592-019-0344-8","volume":"16","author":"K D\u00fchrkop","year":"2019","unstructured":"D\u00fchrkop, K. et al. SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite structure information. Nat. Methods 16, 299\u2013302 (2019).","journal-title":"Nat. Methods"},{"key":"77106_CR26","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00204-014-1206-x","volume":"88","author":"K Kittler","year":"2014","unstructured":"Kittler, K., Fessard, V., Maul, R. & Hurtaud-Pessel, D. CYP3A4 activity reduces the cytotoxic effects of okadaic acid in HepaRG cells. Arch. Toxicol. 88, 1519\u20131526 (2014).","journal-title":"Arch. Toxicol."},{"key":"77106_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tiv.2016.02.021","volume":"33","author":"P-J Ferron","year":"2016","unstructured":"Ferron, P.-J. et al. Modulation of CYP3A4 activity alters the cytotoxicity of lipophilic phycotoxins in human hepatic HepaRG cells. Toxicol. in Vitro 33, 136\u2013146 (2016).","journal-title":"Toxicol. in Vitro"},{"key":"77106_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/BF02353474","volume":"24","author":"SA Wrighton","year":"1996","unstructured":"Wrighton, S. A., VandenBranden, M. & Ring, B. J. The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. 24, 461\u2013473 (1996).","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"77106_CR29","doi-asserted-by":"publisher","unstructured":"Cytochrome P450: Structure, Mechanism, and Biochemistry. (Springer International Publishing, 2015). https:\/\/doi.org\/10.1007\/978-3-319-12108-6.","DOI":"10.1007\/978-3-319-12108-6"},{"key":"77106_CR30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1124\/dmd.116.069831","volume":"44","author":"JP Jackson","year":"2016","unstructured":"Jackson, J. P., Li, L., Chamberlain, E. D., Wang, H. & Ferguson, S. S. Contextualizing hepatocyte functionality of cryopreserved HepaRG cell cultures. Drug Metab. Dispos. 44, 1463\u20131479 (2016).","journal-title":"Drug Metab. Dispos."},{"key":"77106_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","volume":"63","author":"DJ Greenblatt","year":"2011","unstructured":"Greenblatt, D. J. et al. Mechanism of cytochrome P450\u20133A inhibition by ketoconazole: Ketoconazole inhibition of CYP3A. J. Pharm. Pharmacol. 63, 214\u2013221 (2011).","journal-title":"J. Pharm. Pharmacol."},{"key":"77106_CR32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/1389200215666141125121511","volume":"15","author":"T Niwa","year":"2015","unstructured":"Niwa, T., Imagawa, Y. & Yamazaki, H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr. Drug Metab. 15, 651\u2013679 (2015).","journal-title":"Curr. Drug Metab."},{"key":"77106_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","volume":"38","author":"K Venkatakrishnan","year":"2000","unstructured":"Venkatakrishnan, K., von Moltke, L. L. & Greenblatt, D. J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38, 111\u2013180 (2000).","journal-title":"Clin. Pharmacokinet."},{"key":"77106_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/0091270008331196","volume":"49","author":"P Zhao","year":"2009","unstructured":"Zhao, P. et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J. Clin. Pharmacol. 49, 351\u2013359 (2009).","journal-title":"J. Clin. Pharmacol."},{"key":"77106_CR35","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1038\/s41598-017-15033-0","volume":"7","author":"S Abe","year":"2017","unstructured":"Abe, S. et al. Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology. Sci. Rep. 7, 15189 (2017).","journal-title":"Sci. Rep."},{"key":"77106_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00228-006-0230-z","volume":"63","author":"A Allqvist","year":"2007","unstructured":"Allqvist, A., Miura, J., Bertilsson, L. & Mirghani, R. A. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol. 63, 173\u2013179 (2007).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"77106_CR37","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1124\/dmd.114.057000","volume":"42","author":"E Tseng","year":"2014","unstructured":"Tseng, E. et al. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metab. Dispos. 42, 1163\u20131173 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"77106_CR38","doi-asserted-by":"publisher","first-page":"33711","DOI":"10.1074\/jbc.M205146200","volume":"277","author":"FP Guengerich","year":"2002","unstructured":"Guengerich, F. P., Miller, G. P., Hanna, I. H., Sato, H. & Martin, M. V. Oxidation of methoxyphenethylamines by cytochrome P450 2D6: analysis of rate-limiting steps. J. Biol. Chem. 277, 33711\u201333719 (2002).","journal-title":"J. Biol. Chem."},{"key":"77106_CR39","first-page":"287","volume":"30","author":"FP Guengerich","year":"1986","unstructured":"Guengerich, F. P., M\u00fcller-Enoch, D. & Blair, I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30, 287\u2013295 (1986).","journal-title":"Mol. Pharmacol."},{"key":"77106_CR40","first-page":"15","volume":"16","author":"SV Otton","year":"1988","unstructured":"Otton, S. V., Brinn, R. U. & Gram, L. F. In vitro evidence against the oxidation of quinidine by the sparteine\/debrisoquine monooxygenase of human liver. Drug Metab. Dispos. Biol. Fate Chem. 16, 15\u201317 (1988).","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"77106_CR41","doi-asserted-by":"publisher","first-page":"38617","DOI":"10.1074\/jbc.M505974200","volume":"280","author":"LA McLaughlin","year":"2005","unstructured":"McLaughlin, L. A. et al. Why is quinidine an inhibitor of cytochrome P450 2D6? the role of key active-site residues in quinidine binding. J. Biol. Chem. 280, 38617\u201338624 (2005).","journal-title":"J. Biol. Chem."},{"key":"77106_CR42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1248\/bpb.b17-00913","volume":"41","author":"Y Yokoyama","year":"2018","unstructured":"Yokoyama, Y. et al. Comparison of drug metabolism and its related hepatotoxic effects in HepaRG, cryopreserved human hepatocytes, and HepG2 cell cultures. Biol. Pharm. Bull. 41, 722\u2013732 (2018).","journal-title":"Biol. Pharm. Bull."},{"key":"77106_CR43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1124\/jpet.117.246751","volume":"365","author":"D Le Guillou","year":"2018","unstructured":"Le Guillou, D. et al. Drug-induced alterations of mitochondrial DNA homeostasis in steatotic and nonsteatotic HepaRG cells. J. Pharmacol. Exp. Ther. 365, 711\u2013726 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"77106_CR44","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11, 1724\u20131743 (2016).","journal-title":"Nat. Protoc."},{"key":"77106_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/0309-1651(82)90187-4","volume":"6","author":"C Guguen-Guillouzo","year":"1982","unstructured":"Guguen-Guillouzo, C. et al. High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biol. Int. Rep. 6, 625\u2013628 (1982).","journal-title":"Cell Biol. Int. Rep."},{"key":"77106_CR46","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/bioinformatics\/btn323","volume":"24","author":"D Kessner","year":"2008","unstructured":"Kessner, D., Chambers, M., Burke, R., Agus, D. & Mallick, P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics 24, 2534\u20132536 (2008).","journal-title":"Bioinformatics"},{"key":"77106_CR47","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/1471-2105-11-395","volume":"11","author":"T Pluskal","year":"2010","unstructured":"Pluskal, T., Castillo, S., Villar-Briones, A. & Ore\u0161i\u010d, M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinform. 11, 395 (2010).","journal-title":"BMC Bioinform."},{"key":"77106_CR48","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"77106_CR49","unstructured":"HighChem LLC. mzCloud\u2014advanced mass spectral database. https:\/\/www.mzcloud.org\/ (2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77106-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77106-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77106-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:11:30Z","timestamp":1670368290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77106-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77106"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77106-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19921"}}